{"database": "openregs", "table": "documents", "rows": [["FDA-2022-N-2390-0020", "FDA", "FDA-2022-N-2390", "Cover Memorandum to Vanda RE: Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing", "Supporting & Related Material", "Background Material", "2023-06-22T04:00:00Z", 2023, 6, null, null, "2023-06-22T14:42:06Z", null, 0, 0, "0900006485bb01e9"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2022-N-2390-0020"], "units": {}, "query_ms": 7.474542944692075, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}